President Trump’s bold drug pricing push delivers massive savings on GLP-1 weight loss drugs and fertility treatments, slashing costs by half and putting real relief in Americans’ pockets after years of Big Pharma gouging under leftist policies.
Story Highlights
- Trump’s TrumpRx.gov halves GLP-1 drug prices to $199-$350 monthly from over $1,000, aiding diabetes and obesity patients.
- Fertility drugs like Gonal-F drop to $168 per pen via 84% MFN discounts, saving thousands per IVF cycle.
- Medicare locks in $245 monthly GLP-1 pricing for 24 months, expanding obesity coverage without taxpayer bloat.
- CMS Director Chris Klomp confirms 25% of Americans now fill prescriptions they couldn’t afford before.
Trump Delivers Pharmacy Counter Savings
CMS Medicare Director Chris Klomp announced in April 2026 that President Trump’s initiatives had halved the cost of GLP-1 drugs like Ozempic, Wegovy, and Zepbound, now averaging $350 per month on TrumpRx.gov for cash-pay patients.
Medicare beneficiaries pay just $245 per month, locked for 24 months. These drugs treat diabetes and obesity, conditions affecting millions strained by prior high prices exceeding $1,000 monthly.
Klomp emphasized that this addresses affordability barriers for a quarter of Americans who cannot fill prescriptions, delivering immediate relief through direct negotiations.
Key Deals with Pharma Giants
Early 2026 pricing agreements with Eli Lilly and Novo Nordisk brought GLP-1 vials to TrumpRx at reduced rates, with introductory prices as low as $199 expiring in spring 2026.
In October 2025, Trump secured an 84% most-favored-nation discount from EMD Serono on IVF drugs: Gonal-F at $168 per pen, Cetrotide at $22.50, and Ovidrel at $84.
These deals tie discounts to domestic manufacturing commitments and tariff exemptions, bypassing Congress for swift action. Pharma gains Medicare obesity coverage expansions in exchange.
Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp
— FOX Business (@FoxBusiness) April 7, 2026
Fertility Treatment Breakthrough for Families
Fertility medications previously costing $3,000-$7,000 per IVF cycle now offer thousands in savings per treatment, easing burdens on families seeking to build households.
EMD Serono’s MFN pricing via TrumpRx makes drugs like Gonal-F accessible at the counter, contrasting out-of-pocket nightmares under past administrations.
This aligns with Trump’s IVF executive order, prioritizing American families over globalist pricing schemes that priced hope out of reach for everyday patriots.
TrumpRx.gov, launched in February 2026, operationalizes these cuts for cash-pay users while Medicare rollouts enable broader access.
Refill rules, such as a 45-day limit on Zepbound, help ensure sustainability, though some promotional pricing phases out.
Critics note similarities to existing coupons, but Klomp’s data shows unique patient-level impacts for high-demand drugs without generics.
Real Wins Against Big Pharma Excess
Building on first-term efforts like insulin caps, Trump’s second-term strategy leverages regulatory authority to pursue voluntary deals, avoiding bloated legislative overreach.
Patients with obesity, diabetes, and infertility—over 22 million at risk of cost-driven dropout—gain out-of-pocket reductions.
Economic impacts include $2,000+ in fertility-cycle savings, spurring U.S. production through tariff incentives.
This common-sense approach boosts access while curbing spending, proving executive action trumps leftist fiscal mismanagement.
Sources:
President Trump Launches TrumpRx.gov Delivering Massive Immediate Savings to Millions of Americans
TrumpRx Discounts Only One Drug While 22 Million Americans See Costs Rise
Evaluating the Trump Administration’s Initiative on IVF
Trump Wrong on Drug Pricing in State of the Union?
